Table 1.
Participants’ characteristics
| ID# | Clinical diagnosis | Pathological diagnosis | Age at death (years) | Gender | PMI (hours) | Braak & Braak (NFT) | CERAD score (neuritic plaques) | NIA-Reagan Institute criteria |
|---|---|---|---|---|---|---|---|---|
| #1 | CTL | Normal adult brain | 86 | M | 16 | I | none | LP |
| #2 | CTL | Normal adult brain | 73 | F | 34 | I | none | LP |
| #3 | AD | AD + occipital CAA | 64 | F | 38 | VI | C | HP |
| #4 | AD | AD | 60 | M | 24 | VI | C | HP |
| #5 | AD | AD | 56 | F | N/A | VI | C | HP |
| #6 | Memory, speech and gait difficulties, hand tremor | Diffuse CAA (D23N Iowa APP mutation) | 45 | M | N/A | I | none | LP |
| #7 | FTD | PiD | 62 | M | 24 | I | A | LP |
| #8 | FTD | PiD, type A | 72 | F | N/A | I | none | LP |
| #9 | FTD | PiD, type A | 82 | M | N/A | II | A | LP |
| #10 | PSP/FTD | PSP | 63 | F | 12 | II | none | LP |
| #11 | PSP | PSP | 69 | M | 45 | II | none | LP |
| #12 | PSP | PSP | 68 | M | 80 | II | none | LP |
| #13 | CBD | CBD | 80 | M | N/A | I | none | LP |
| #14 | FTD | CBD | 83 | M | N/A | I | A | LP |
| #15 | DLB | DLB | 76 | M | 17 | II | none | LP |
| #16 | DLB | DLB (Braak stage 5/6) | 76 | M | 10 | I | none | LP |
| #17 | PDD | DLB (Braak stage 4/6) | 83 | M | 9 | III | none | LP |
| #18 | MSA | MSA, cerebellar type (MSA-C) | 60 | F | 32 | II | none | LP |
| #19 | MSA | MSA, Parkinsonian type (MSA-P) | 80 | M | 25 | I | none | LP |
| #20 | FTD | FTLD-TDP-43, type A | 69 | F | N/A | I | none | LP |
| #21 | AD | Metastatic melanoma in frontal and parietal lobes bilaterally | 75 | M | 35 | V | B | IP |
| #22 | Dementia, ataxia, dysphagia, hearing loss | Superficial siderosis | 68 | M | 12 | I | A | LP |
| #23 | Headache | Subarachnoid hemorrhage | 92 | F | N/A | IV | A | IP |
| #24 | N/A | Parenchymal hemorrhage | 75 | M | N/A | I | none | LP |
Abbreviations: AD = Alzheimer’s disease, APP = amyloid precursor protein, CAA = cerebral amyloid angiopathy, CBD = corticobasal degeneration, CERAD = Consortium to establish a Registry for Alzheimer’s disease, CTL = control subject, DLB = dementia with Lewy bodies, F = female, FTLD = frontotemporal lobar degeneration, HP = high probability, IP =intermediate probability, LP = low probability, M = male, MSA= multiple systemic atrophy, NFT = neurofibrillary tangles, NIA = National Institute of Aging, N/A = non available, PiD = Pick disease, PMI = postmortem interval, PSP = progressive supranuclear palsy, TDP-43 = TAR DNA binding protein 43